Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies.

ABSTRACT: Human monoclonal antibodies (mAbs) that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been isolated from convalescent individuals and developed into therapeutics for SARS-CoV-2 infection. However, therapeutic mAbs for SARS-CoV-2 have been rendered obsolete by the emergence of mAb-resistant virus variants. Here we report the generation of a set of six human mAbs that bind the human angiotensin-converting enzyme-2 (hACE2) receptor, rather than the SARS-CoV-2 spike protein. We show that these antibodies block infection by all hACE2 binding sarbecoviruses tested, including SARS-CoV-2 ancestral, Delta and Omicron variants at concentrations of ~7-100 ng ml^-1. These antibodies target an hACE2 epitope that binds to the SARS-CoV-2 spike, but t

SUBMITTER: Zhang F 

PROVIDER: S-EPMC10234812 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature